Almirall, Quintiles sign long-term commercial U.K. partnership

Monday, July 30, 2012 10:52 AM

Global pharmaceutical company Almirall and Quintiles, a fully integrated biopharmaceutical services company, have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the U.K. commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

After the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion for the regulatory approval of Almirall’s new LAMA as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD on May 28, 2012, the European Commission finally approved the medicine on July 24.

“We are proud to bring the first product in a truly innovative respiratory franchise to the U.K. market. Our long-term alignment with Quintiles will help us to ensure that new therapeutic options are made available for COPD patients throughout the U.K.,” said Carlos Gallardo, general manager, Almirall U.K.

This strategic partnership deepens the relationship between the two organizations: Quintiles conducted part of the clinical study program in COPD and provides commercialization services to Almirall in multiple European countries.

The FDA also issued final positive feedback on Almirall’s first product in COPD on July 24.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs